Structure Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
Provided By GlobeNewswire
Last update: Aug 6, 2025
Topline data from oral small molecule GLP-1 receptor agonist aleniglipron ACCESS and ACCESS II
studies on track for year-end 2025 readouts
Aleniglipron clinical development program expanded to optimize competitive positioning and
Phase 3 program
